Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers

Open access
Eisen, A., Lubinski, J., Gronwald, J., Moller, P., Lynch, H. T., Klijn, J., Kim-Sing, C., Neuhausen, S. L., Gilbert, L., Ghadirian, P., Manoukian, S., Rennert, G., Friedman, E., Isaacs, C., Rosen, E., Rosen, B., Daly, M., Sun, P., Narod, S. A., the Hereditary Breast Cancer Clinical Study Group · 2008 · JNCI Journal of the National Cancer Institute

Abstract

BACKGROUND: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. METHODS: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. RESULTS: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P = .03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P = .04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P = .21). CONCLUSION: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djn313

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 194

Metadata

Authors
Eisen, A., Lubinski, J., Gronwald, J., Moller, P., Lynch, H. T., Klijn, J., Kim-Sing, C., Neuhausen, S. L., Gilbert, L., Ghadirian, P., Manoukian, S., Rennert, G., Friedman, E., Isaacs, C., Rosen, E., Rosen, B., Daly, M., Sun, P., Narod, S. A., & the Hereditary Breast Cancer Clinical Study Group
Venue
JNCI Journal of the National Cancer Institute
Published
2008-09-23
Volume
100
Issue
19
Pages
1361-1367
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2159127722
Cited by
194
References
2
FWCI
8.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. https://app.cochat.ai/papers/10.1093/jnci/djn313
The paper
Eisen, A., Lubinski, J., Gronwald, J., Moller, P., Lynch, H. T., Klijn, J., Kim-Sing, C., Neuhausen, S. L., Gilbert, L., Ghadirian, P., Manoukian, S., Rennert, G., Friedman, E., Isaacs, C., Rosen, E., Rosen, B., Daly, M., Sun, P., Narod, S. A., & the Hereditary Breast Cancer Clinical Study Group. (2008). Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djn313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.